Drug Trial Radar · NCT05890794
Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia
Last checked: Nov 19, 2026Latest source record: Feb 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
May 15, 2023
Primary completion
Jul 7, 2023
Study completion Jul 12, 2023
Sponsor
- Lead sponsor
- AM-PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jun 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to compare the effectiveness of two doses of ilofotase alfa, an enzyme replacement treatment, in patients with hypophosphatasia (HPP). The main question it aims to answer is if the harmful accumulating levels of extracellular inorganic pyrophosphate (PPi) and pyridoxal 5'-phosphate (PLP) can be reduced with ilofotase alfa. Researchers will compare the two doses of ilofotase alfa to see if treatment effects differ between the doses.
Conditions
- Hypophosphatasia
Interventions
Ilofotase Alfa, 0.8 mg/kgBiological
Biological: single 1-hour intravenous infusion of 0.8 mg/kg ilofotase alfa
Ilofotase Alfa, 3.2 mg/kgBiological
Biological: single 1-hour intravenous infusion of 3.2 mg/kg ilofotase alfa
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Percent Change From Baseline in Extracellular Inorganic Pyrophosphate (PPi)Time frame: Day 1 to Day 10
- Maximum Percent Change From Baseline in Pyridoxal 5'-Phosphate (PLP)Time frame: Day 1 to Day 10
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Osteologie / Klinische Studieneinheit, Orthopädische Klinik - KLH
Würzburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.